MX2011011376A - Preparacion de inmunoglobulina enriquecida con anti-lps, para utilizarse en tratamiento y/o profilaxis de un trastorno patologico. - Google Patents

Preparacion de inmunoglobulina enriquecida con anti-lps, para utilizarse en tratamiento y/o profilaxis de un trastorno patologico.

Info

Publication number
MX2011011376A
MX2011011376A MX2011011376A MX2011011376A MX2011011376A MX 2011011376 A MX2011011376 A MX 2011011376A MX 2011011376 A MX2011011376 A MX 2011011376A MX 2011011376 A MX2011011376 A MX 2011011376A MX 2011011376 A MX2011011376 A MX 2011011376A
Authority
MX
Mexico
Prior art keywords
treatment
pathologic disorder
disorder
prophylaxis
lps
Prior art date
Application number
MX2011011376A
Other languages
English (en)
Spanish (es)
Inventor
Yaron Ilan
Gadi Lalazar
Tomer Adar
Meir Mizrahi
Ami Ben-Ya Acov
Original Assignee
Immuron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuron Ltd filed Critical Immuron Ltd
Publication of MX2011011376A publication Critical patent/MX2011011376A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39508—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from milk, i.e. lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
MX2011011376A 2009-04-27 2010-04-27 Preparacion de inmunoglobulina enriquecida con anti-lps, para utilizarse en tratamiento y/o profilaxis de un trastorno patologico. MX2011011376A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17292209P 2009-04-27 2009-04-27
PCT/IL2010/000339 WO2010125565A2 (en) 2009-04-27 2010-04-27 Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder

Publications (1)

Publication Number Publication Date
MX2011011376A true MX2011011376A (es) 2012-04-20

Family

ID=42357536

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011376A MX2011011376A (es) 2009-04-27 2010-04-27 Preparacion de inmunoglobulina enriquecida con anti-lps, para utilizarse en tratamiento y/o profilaxis de un trastorno patologico.

Country Status (14)

Country Link
US (2) US10117930B2 (https=)
EP (2) EP2424890B1 (https=)
JP (1) JP5740390B2 (https=)
KR (1) KR101785120B1 (https=)
AU (1) AU2010243205B2 (https=)
BR (1) BRPI1014774A2 (https=)
CA (2) CA2760096C (https=)
DK (1) DK2424890T3 (https=)
EA (1) EA024697B1 (https=)
ES (1) ES2684696T3 (https=)
IL (1) IL215924B (https=)
MX (1) MX2011011376A (https=)
SG (1) SG175142A1 (https=)
WO (1) WO2010125565A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012023051A2 (en) 2010-08-17 2012-02-23 Immuron Ltd. Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
TW201304786A (zh) * 2010-10-04 2013-02-01 Immuron Ltd 使用抗ｌｐｓ配體治療及預防發炎疾病的方法及組合物
MY164281A (en) 2010-11-23 2017-11-30 Pantheryx Inc Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
DE102011006781A1 (de) * 2011-04-05 2012-10-11 Mat-Malta Advanced Technologies Limited Antikörperprodukt, umfassend n spezifische Antikörper
DE102011006809A1 (de) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
MX374963B (es) 2011-04-29 2025-03-06 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
WO2012171077A1 (en) * 2011-06-17 2012-12-20 Immuron Limited Method and composition for treatment or inhibition of mucositis associated with chemotherapy or radiation damage
WO2013009843A1 (en) * 2011-07-11 2013-01-17 Camas Incorporated Compositions against bacterial toxins
AU2013204801B2 (en) 2012-05-23 2014-11-06 Omniblend Innovation Pty Ltd Composition and method for management of diabetes or pre-diabetes
EP2864346B1 (en) * 2012-06-21 2018-10-17 Synthon Biopharmaceuticals B.V. Method of purifying an antibody
PL2945651T3 (pl) 2013-01-17 2018-08-31 Arsanis Biosciences Gmbh Przeciwciało swoiste wobec E.coli MDR
BR122020023215B1 (pt) 2013-05-03 2022-11-22 Selecta Biosciences, Inc Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico
WO2015063693A1 (en) * 2013-10-30 2015-05-07 Hadasit Medical Research Services And Development Limited Anti-lps enriched immunoglobulin for use in treatment and/or prophylaxis of fibrosis
WO2015117711A1 (en) 2014-02-06 2015-08-13 Arsanis Biosciences Gmbh E. coli specific antibody sequences
WO2015124769A1 (en) 2014-02-24 2015-08-27 Glycovaxyn Ag Novel polysaccharide and uses thereof
JP7242180B2 (ja) 2014-09-07 2023-03-20 セレクタ バイオサイエンシーズ インコーポレーテッド 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AU2017260881A1 (en) * 2016-05-06 2018-12-20 Hadasit Medical Research Services & Development Limited Hyperimmune colostrum in the modulation and treatment of conditions associated with the mammailan microbiome
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
ES3036482T3 (en) 2017-03-11 2025-09-19 Cartesian Therapeutics Inc Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
CA3105117A1 (en) * 2018-07-02 2020-01-09 Puretech Lyt, Inc. Milk vesicles for use in delivering biological agents
CN112996808A (zh) * 2018-10-03 2021-06-18 埃努贝尔拜欧公司 用于治疗动物急性腹泻和肠道感染的组合物和方法
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
CN113365637A (zh) * 2018-12-05 2021-09-07 维京治疗公司 用于治疗肝部病症的组合物和方法
WO2020176637A1 (en) 2019-02-26 2020-09-03 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract
CA3134216A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
AU2020287627A1 (en) 2019-06-04 2021-11-18 Selecta Biosciences, Inc. Formulations and doses of PEGylated uricase
US20210252149A1 (en) * 2020-02-19 2021-08-19 Anubis Bio Corporation Composition and Methods for Treating Infectious Agents Using Pathogen-specific Antibodies
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
WO2022221616A1 (en) 2021-04-16 2022-10-20 Prodigy Biotech Hyperimmunized egg product for treating or preventing alcoholic liver disease and graft-versus-host disease
US20250051426A1 (en) * 2021-09-30 2025-02-13 Igalphan corporation Composition containing monoclonal antibody
WO2025188199A1 (en) * 2024-03-06 2025-09-12 Koru Biotech Solutions Limited Therapeutic and prophylactic agents and related compositions and methods

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH627079A5 (en) 1977-04-15 1981-12-31 Nestle Sa Process for preparing a protein concentrate containing immunological factors of milk origin
US4550019A (en) 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
JPS58154513A (ja) 1982-03-09 1983-09-14 Sendai Biseibutsu Kenkyusho 予防及び治療薬
US4748018A (en) 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
GB9105292D0 (en) * 1991-03-13 1991-04-24 Sandoz Ltd Improvements in or relating to organic compounds
DE69432309D1 (de) 1993-09-20 2003-04-24 Anadis Ltd Verfahren zur herstellung von immunoglobulinen aus colostrum und deren verwendung in pharmazeutischen zusammensetzungen
DE4337654C2 (de) 1993-11-04 1996-08-08 Biotest Pharma Gmbh Verwendung boviner Kolostralmilch von nicht mit Viren hyperimmunisierten Tieren als Leberschutzpräparat
ID26730A (id) 1998-05-27 2001-02-01 Gemma Biotechnology Ltd Induksi protein-protein dan peptida-peptida antibiotik oleh lait/scd14-protein
DE19830607C2 (de) 1998-07-09 2002-08-01 Hte Ag The High Throughput Exp Verfahren zum Nachweis eines Produktes im Abstrom eines katalytischen Materials einer Vielzahl von katalytischen Materialien
US20050175597A1 (en) 2002-03-21 2005-08-11 Rawlin Grant T. Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment
CA2486801A1 (en) 2002-05-21 2003-11-27 Anadis Ltd Method of prophylaxis of infection
US9701737B2 (en) 2003-02-19 2017-07-11 Camas, Incorporated Immunogen adherence and method of making and using same
AU2003901008A0 (en) 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
WO2006035979A1 (ja) * 2004-09-29 2006-04-06 Asama Chemical Co., Ltd. 乳清タンパク、乳由来の抗体または抗体を含む機能性組成物または食品
AU2005306579B2 (en) 2004-11-22 2012-01-19 Immuron Limited Bioactive compositions
DK2061510T3 (en) * 2006-08-31 2016-09-05 A C N 135 493 391 Pty Ltd As Trustee For Conca Unit Trust Treatment and / or prevention of Barrett's esophagus using anti-EphB4 antibody-containing compositions
WO2009113065A1 (en) 2008-03-13 2009-09-17 Hadasit Medical Research Services & Development Ltd. Immuno-modulating compositions for the treatment of immune-mediated disorders
WO2012023051A2 (en) 2010-08-17 2012-02-23 Immuron Ltd. Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder

Also Published As

Publication number Publication date
CA3017477A1 (en) 2010-11-04
US20190209681A1 (en) 2019-07-11
ES2684696T3 (es) 2018-10-04
CA2760096C (en) 2018-10-30
JP5740390B2 (ja) 2015-06-24
IL215924A0 (en) 2011-12-29
WO2010125565A3 (en) 2011-01-27
US20120135007A1 (en) 2012-05-31
EP2424890B1 (en) 2018-08-01
IL215924B (en) 2018-01-31
EA024697B1 (ru) 2016-10-31
SG175142A1 (en) 2011-12-29
EA201171304A1 (ru) 2012-06-29
AU2010243205B2 (en) 2014-09-11
EP2424890A2 (en) 2012-03-07
WO2010125565A2 (en) 2010-11-04
BRPI1014774A2 (pt) 2019-04-16
US10117930B2 (en) 2018-11-06
DK2424890T3 (en) 2018-09-17
CA2760096A1 (en) 2010-11-04
KR101785120B1 (ko) 2017-10-12
EP3461840A1 (en) 2019-04-03
AU2010243205A1 (en) 2011-12-01
KR20120061067A (ko) 2012-06-12
JP2012525376A (ja) 2012-10-22

Similar Documents

Publication Publication Date Title
MX2011011376A (es) Preparacion de inmunoglobulina enriquecida con anti-lps, para utilizarse en tratamiento y/o profilaxis de un trastorno patologico.
WO2008033966A3 (en) Alphavirus replicon particles matched to protein antigens as immunological adjuvants
WO2012088247A3 (en) Anti-c5/c5a/c5adesr antibodies and fragments
WO2010104761A3 (en) Anti-cd40 antibodies and uses thereof
PE20141188A1 (es) Polipeptidos anticuerpos que antagonizan cd40
EA036814B9 (ru) Антитело против pd-l1 (варианты), композиция, содержащая это антитело, и их применение
WO2013011076A3 (en) Tnf -alpha antigen- binding proteins with increased fcrn binding
EA201790342A1 (ru) Антитела к trem2 и способы их применения
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
IN2015DN00091A (https=)
WO2009117030A3 (en) Improved compositions for the prevention and treatment of smallpox
MY153893A (en) Antibodies against human il17 and uses thereof
EP4467648A3 (en) Anti-dr5 antibodies and methods of use thereof
WO2014114651A9 (en) Tnf-alpha antigen-binding proteins
NZ602548A (en) Oligomer-specific amyloid beta epitope and antibodies
WO2012156532A8 (en) Anti-human-her3 antibodies and uses thereof
WO2012114125A3 (en) Treatment and prevention of malaria
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
EA201491851A1 (ru) Композиции и способы для лечения болезни альцгеймера
UA117657C2 (uk) Антитіло до трансглютамінази 2 (tg2)
MX2022001604A (es) Anticuerpos anti bdca-2.
WO2016016651A3 (en) Pfrh5 derived antigen for treatment of malaria
MY210018A (en) Monoclonal antibody that binds specifically to gitr
HK1199038A1 (en) Anti-human xcr1 antibodies
BR112018009882A2 (pt) gradientes de ph-sal opostos para separações melhoradas de proteína